E-resources
-
Abida, Wassim; Cyrta, Joanna; Heller, Glenn; Prandi, Davide; Armenia, Joshua; Coleman, Ilsa; Cieslik, Marcin; Benelli, Matteo; Robinson, Dan; Van Allen, Eliezer M.; Sboner, Andrea; Fedrizzi, Tarcisio; Mosquera, Juan Miguel; Robinson, Brian D.; De Sarkar, Navonil; Kunju, Lakshmi P.; Tomlins, Scott; Wu, Yi Mi; Rodrigues, Daniel Nava; Loda, Massimo; Gopalan, Anuradha; Reuter, Victor E.; Pritchard, Colin C.; Mateo, Joaquin; Bianchini, Diletta; Miranda, Susana; Carreira, Suzanne; Rescigno, Pasquale; Filipenko, Julie; Vinson, Jacob; Montgomery, Robert B.; Beltran, Himisha; Heath, Elisabeth I.; Scher, Howard I.; Kantoff, Philip W.; Taplin, Mary-Ellen; Schultz, Nikolaus; deBono, Johann S.; Demichelis, Francesca; Nelson, Peter S.; Rubin, Mark A.; Chinnaiyan, Arul M.; Sawyers, Charles L.
Proceedings of the National Academy of Sciences - PNAS, 06/2019, Volume: 116, Issue: 23Journal Article
Heterogeneity in the genomic landscape of metastatic prostate cancer has become apparent through several comprehensive profiling efforts, but little is known about the impact of this heterogeneity on clinical outcome. Here, we report comprehensive genomic and transcriptomic analysis of 429 patients with metastatic castration-resistant prostate cancer (mCRPC) linked with longitudinal clinical outcomes, integrating findings from whole-exome, transcriptome, and histologic analysis. For 128 patients treated with a first-line next-generation androgen receptor signaling inhibitor (ARSI; abiraterone or enzalutamide), we examined the association of 18 recurrent DNA- and RNA-based genomic alterations, including androgen receptor (AR) variant expression, AR transcriptional output, and neuroendocrine expression signatures, with clinical outcomes. Of these, only RB1 alteration was significantly associated with poor survival, whereas alterations in RB1, AR, and TP53 were associated with shorter time on treatment with an ARSI. This large analysis integrating mCRPC genomics with histology and clinical outcomes identifies RB1 genomic alteration as a potent predictor of poor outcome, and is a community resource for further interrogation of clinical and molecular associations.
Author
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.